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The human JC polyomavirus (JCV) causes a fatal
demyelinating disease, progressive multifocal leu-
koencephalopathy (PML), in immunocompromised
individuals. Current treatment options for PML are
inadequate. Sialylated oligosaccharides and the
serotonin receptor are known to be necessary for
JCV entry, but the molecular interactions underlying
JCV attachment remain unknown. Using glycan array
screening and viral infectivity assays, we identify a
linear sialylated pentasaccharide with the sequence
NeuNAc-a2,6-Gal-b1,4-GlcNAc-b1,3-Gal-b1,4-Glc
(LSTc) present on host glycoproteins and glycolipids
as a specific JCV recognitionmotif. The crystal struc-
ture of the JCV capsid protein VP1 was solved alone
and in complex with LSTc. It reveals extensive inter-
actions with the terminal sialic acid of the LSTc motif
and specific recognition of an extended conforma-
tion of LSTc. Mutations in the JCV oligosaccharide-
binding sites abolish cell attachment, viral spread,
and infectivity, further validating the importance of
this interaction. Our findings provide a powerful plat-
form for the development of antiviral compounds.
INTRODUCTION
The human JC polyomavirus (JCV) is a member of the Polyoma-
viridae family, which also includes simian virus 40 (SV40), murine
polyomavirus (Polyoma), and the human BK virus (BKV). JCV is
a significant human pathogen for which approximately 50%–
80% of individuals are seropositive (Kean et al., 2009; Knowles
et al., 2003). JCV establishes a persistent, mostly asymptomatic
infection in the kidney (Dorries, 1998). However, the virus can
become reactivated in immunosuppressed hosts, leading to
enhanced viral replication and infection of glial cells, including
astrocytes and the myelin-producing oligodendrocytes, in the
central nervous system (CNS). JCV infection leads to cytolyticCell Hosdestruction of oligodendroglia and causes the fatal disease
progressive multifocal leukoencephalopathy (PML) (Khalili and
White, 2006; Seth et al., 2003; Silverman and Rubinstein, 1965;
Zurhein and Chou, 1965). PML is commonly associated with
human immunodeficiency virus (HIV) and acquired immunodefi-
ciency syndrome (AIDS) (Cinque et al., 2009). However, the
incidence of PML has increased recently in patients receiving
immunosuppressive therapies for autoimmune diseases (Carson
et al., 2009b; Major, 2009; Van Assche et al., 2005). The prog-
nosis of PML is bleak, as it usually proves fatal within 1 year of
symptom onset. Currently there are few treatments for PML
(Kishida, 2007).
JCV has a nonenveloped, icosahedral capsid that encloses
a circular double-stranded DNA genome (Shah et al., 1996).
Themajor component of the capsid is viral protein 1 (VP1). Struc-
tural studies of SV40 and Polyoma virions revealed that polyo-
mavirus capsids consist of 72 VP1 pentamers that are linked
via C-terminal extensions of VP1 (Liddington et al., 1991; Stehle
et al., 1994). VP1 attaches to receptors on host cells and thereby
initiates infection. In crystal structures of Polyoma and SV40
receptor complexes, the receptor binding site is formed by
VP1 loops at the outer surface of the capsid (Neu et al., 2008;
Stehle et al., 1994). JCV is internalized into cells via clathrin-
dependent endocytosis (Pho et al., 2000) and traffics through
endosomes and caveosomes (Querbes et al., 2006) to the
endoplasmic reticulum (ER). Viral uncoating is thought to begin
in the ER, followed by translocation to the cytosol and transport
of the genome to the nucleus for viral replication. Previous
studies have shown that sialylated oligosaccharides (Dugan
et al., 2008; Komagome et al., 2002; Liu et al., 1998b) and the
serotonin receptor 5-HT2AR (Elphick et al., 2004) are necessary
for JCV entry. The predominant sialic acid in humans is a-5-N-
acetyl neuraminic acid (NeuNAc), which caps many different
oligosaccharide structures (Varki, 2001).
In this study, we demonstrate that JCV binds specifically to the
oligosaccharide lactoseries tetrasaccharide c (LSTc), which
contains an a2,6-linked NeuNAc, using a glycan array screen.
The relevance of LSTc as a functional receptor for JCV is
confirmed through infectivity assays. We determined the crystal
structure of JCV VP1 in complex with LSTc, and based on the
structural analysis performed mutagenesis experiments thatt & Microbe 8, 309–319, October 21, 2010 ª2010 Elsevier Inc. 309
Figure 1. LSTc Is a Functional, Specific Receptor Motif for JCV
(A) Glycan microarray analysis of JCV VP1 showing highly selective binding to LSTc. Numerical scores for the binding intensity are shown as means of fluores-
cence intensities of duplicate spots at 2 (in blue) and 5 (in red) fmol/spot. Error bars represent half of the difference between the two values.
(B) Structures of selected glycans present on the glycan microarray. The oligosaccharide sequence of the LSTc probe is shown, as well as those of similar
compounds that were not bound.
(C) LSTc inhibits JCV Infection. JC virus was preincubated with LSTb or LSTc, and complexes were added to SVG-A cells for infection. Infected cells were quan-
tified based on nuclear VP1 staining. The data represent the average number of infected cells per visual field for eight fields of view from an experiment performed
in triplicate. Error bars indicate SD of triplicate samples. *p < 0.05.
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JCV Attachment to Its Glycan Receptor Motif LSTcprobe the specificity of JCVbinding to LSTc. Thesestudies estab-
lish the mechanism of JCV cell attachment and provide a founda-
tion for strategies to intervene in the attachment process.
RESULTS
JCV Specifically Engages the Oligosaccharide LSTc
Whereas it is clearly established that JCV infection depends on
interaction between VP1 and sialic acid, the nature of the oligo-
saccharide receptor has remained elusive. To approach this
problem, we expressed recombinant JCV VP1 pentamers
(Neu et al., 2008; Stehle and Harrison, 1997). The purified pen-
tamers were analyzed on glycan microarrays containing 81
lipid-linked sialylated oligosaccharides differing in the sialyl
linkage, backbone sequences, chain lengths, and branching
patterns. The microarrays represented carbohydrates found on
N- and O-linked glycoproteins as well as glycolipids (see Table
S1 available online). JCV VP1 bound specifically to a2,6-linked
LSTc (Figure 1A). LSTc is a linear pentasaccharide with the
sequence NeuNAc-a2,6-Gal-b1,4-GlcNAc-b1,3-Gal-b1,4-Glc.
This sequence represents the type that occurs in the peripheral
region of glycans of glycoproteins and glycolipids. The glycan
array contained several sequences that closely resembled
LSTc, but VP1 did not bind to these (Figures 1A and 1B).310 Cell Host & Microbe 8, 309–319, October 21, 2010 ª2010 ElsevieTo determine whether JCV engages LSTc to mediate infection
of host cells, JCV was preincubated with LSTc, and the mixture
was added to SVG-A cells, a glial cell line permissive for JCV.
The JCV/LSTc mixture significantly reduced JCV infection, while
incubation with JCV/LSTb had no effect on infection (Figure 1C).
LSTb is identical to LSTc in molecular weight and composition
but features a branching a2,6-linked sialic acid (Figure 1B).
Thus, the specific engagement of an LSTc-like sequence on
host cells is critical for JCV infection.
Overall Structure of the JCV VP1-LSTc Complex
We solved the crystal structure of a JCV VP1 pentamer in
complex with LSTc at 2.0 A˚ resolution (Figure 2A, Table 1). The
final structure contains amino acids 25–85 and 100–287 for all
five VP1 chains. Each VP1 monomer adopts the antiparallel
b sandwich fold iconic for viral capsid proteins. Two four-
stranded b sheets pack against each other. Their strands are
linked by loops in a way that gives rise to a jelly roll topology,
with the two b sheets consisting of strands B, I, D, G and C, H,
E, F, respectively.
LSTc binds on top of the JCV VP1 pentamer, on the outer
surface of the virion (Figures 2A and 2B). Two of the five possible
binding sites on VP1 contain LSTc, the other three are occluded
by crystal contacts. In the context of cell attachment by an entirer Inc.
Figure 2. Structure of JCV VP1 in Complex
with LSTc
(A) Structure of the JCV VP1 pentamer in complex
with LSTc. The protein is shown in cartoon repre-
sentation, with one VP1 monomer highlighted in
pink and the other monomers depicted in gray.
The LSTc oligosaccharide is drawn as a stick
model and colored according to atom type (nitro-
gens in blue, oxygens in red, and carbons in
orange).
(B) Close-up view of the LSTc binding site. JCV
VP1 and LSTc are drawn as in (A). A composite an-
nealed omit difference density map of LSTc is
shown contoured at 3.0 s for 2.0 A˚ around LSTc.
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JCV Attachment to Its Glycan Receptor Motif LSTcvirion, however, all five binding sites on a given pentamer could
be occupied by LSTc, which is not unlikely, given the relatively
low affinity of a single protein-carbohydrate interaction. The
binding site is formed by residues from the BC, DE, and HI loops
from one monomer as well as the BC loop from its clockwise
neighbor (Figure 2B). These loops also engage receptors in
SV40 and Polyoma VP1, and they are the only parts of VP1
that differ significantly among the three viruses (Neu et al.,
2008; Stehle and Harrison, 1997). The extensive BC loop can
be subdivided into two parts facing in different directions (BC1
and BC2). LSTc binds where the BC1 loop of one monomerTable 1. Crystallographic Statistics of JCV VP1 and JCV VP1-
LSTc Structures
JCV VP1-LSTc Complex JCV VP1
Data Collection
Unit cell (A˚) 149.7, 96.3, 128.2 149.6, 96.0, 128.6
Unit cell () 90, 110.3, 90 90, 110.4, 90
Space group C2 C2
Resolution (A˚) 35–2.0 2.05 –2.00 20–1.95 2.00–1.95
Total reflections 437,707 30,603 419,669 15,867
Unique reflections 114,938 8,302 119,853 8,429
I/sI 9.6 2.7 10.9 2.5
Rmerge (%) 11.7 48.3 9.3 32.4
Completeness (%) 99.5 97.5 96.5 91.7
Structure Refinement
Protein atoms 10,200 10,135
Average B factor (A˚2) 16.6 15.7
Carbohydrate atoms 136 -
Average B factor (A˚2) 24.3 -
Solvent atoms 980 1,054
Average B factor (A˚2) 25.4 26.4
Rwork (%) 18.9 18.0







Cell Hosapproaches the tip of the BC2 loop of its clockwise neighbor,
and it interacts with both. For reasons of clarity, residues and
loops of the main binding VP1 monomer will not be specifically
labeled, while those of its clockwise and counterclockwise
neighbors will be designated cw and ccw, respectively, herein.Interactions of JCV VP1 with LSTc
The bound LSTc molecule resembles the letter ‘‘L,’’ with the
shorter leg formed by NeuNAc and its a2,6-linkage to Gal, and
the longer leg consisting of the GlcNAc-b1,3-Gal-b1,4-Glc
trisaccharide (Figure 2B). In solution, the glycosidic bonds of
LSTc can rotate freely due to its unbranched sequence, and
the molecule can assume different conformations (Breg et al.,
1989). However, as the NeuNAc and GlcNAc moieties of LSTc
are attached to positions 6 and 1 of the same Gal residue, all
conformations feature a kink. JCV VP1 interacts selectively
with one of these conformations, contacting sugar moieties in
both legs of the L-shaped ligand. The observed conformation
of LSTc as well as its orientation with respect to the VP1 surface
differs from previously published homology models of JCV inter-
actions with oligosaccharides (Gee et al., 2004; Sunyaev et al.,
2009). These homology models were based on interactions
observed in the structure of Polyoma VP1 in complex with an
a2,3-sialylated oligosaccharide (Stehle and Harrison, 1997).
Although NeuNAc is bound in a similar location at the outer
surface of both proteins, the orientation of NeuNAc with respect
to the protein surface is different, and the interactions with the
oligosaccharide structures are not conserved.
Most of the interactions between JCV and LSTc involve the
three longer functional groups projecting from the terminal Neu-
NAc residue (Figures 3A and 3B). The NeuNAc carboxylate faces
toward the HI loop and is recognized by parallel hydrogen bonds
to the side chains of S266 and S268, as well as a water-mediated
hydrogen bond to S266. The extended NeuNAc glycerol chain
docks into a shallow depression on the protein surface that is
shaped by residues in the BC and HI loops. The bottom of the
depression is formed by the side chain of Q270. Hydrogen bonds
to the amide and hydroxyl groups of S60, located at the rim of the
depression, further anchor the glycerol chain. The methyl moiety
of the N-acetyl group inserts into a hydrophobic cavity at the
intersection between the HI, BC1, and BC2cw loops. Thet & Microbe 8, 309–319, October 21, 2010 ª2010 Elsevier Inc. 311
Figure 3. Interactions between JCV VP1 and LSTc
(A) Interactions between JCV VP1 and the terminal NeuNAc of LSTc. JCV VP1 is shown as a cartoon, with side chains interacting with LSTc in stick representation.
Waters are represented with spheres. Residues forming direct hydrogen bonds to NeuNAc are colored teal and residues forming van der Waals contacts or
water-mediated hydrogen bonds are colored pink. Direct hydrogen bonds between JCV VP1 and NeuNAc are shown as black dashed lines, and water-mediated
hydrogen bonds or bonds between protein atoms are colored gray. Intramolecular hydrogen bonds within the oligosaccharide are orange.
(B) Interactions between JCV VP1 and other parts of LSTc.
(C) The cartoon represents structural features of oligosaccharides that are required for JCV binding. These were extracted from our glycan microarray data.
Crossed-out sugar residues would produce steric clashes.
(D) Structural basis for JCV VP1 specificity for LSTc. JCV is shown in surface representation, with residues interacting with LSTc colored according to their change
in surface accessibility upon LSTc binding (gray <1 A˚2 change, light teal 1–10 A˚2 change, dark teal >10 A˚2 change). The branching substitutions at LSTc that
abolish binding are indicated as black hexagons, indicating where they would clash with protein or LSTc atoms.
(E) Structural changes in JCV VP1 upon LSTc binding. The structures of unliganded (gray) and liganded (pink) JCV VP1 were superposed using the b sandwich
core residues. Hydrogen bonds only present in unliganded VP1 are indicated with green dashes, and those only present in the complex are colored black.
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Finally, the O4 hydroxyl group of NeuNAc forms a hydrogen
bond with the side chain of N123. The O4 hydroxyl group also
makes two water-mediated hydrogen bonds to N123 and
F67cw.
Specific contacts between JCV VP1 and the long leg of the
L-shaped LSTc mostly involve the GlcNAc residue. The side
chain of N123 forms hydrogen bonds to both the carbonyl of
the GlcNAc N-acetyl group and the side chain of R265. In turn,
the carbonyl group of the N-acetyl chain forms water-mediated
hydrogen bonds with S266 and the carboxyl group of the Neu-
NAc residue. The methyl group of the GlcNAc N-acetyl chain
makes van der Waals interactions with the methyl group of
T66cw. In addition, there is a hydrogen bond within LSTc linking
GlcNAc with the glycosidic oxygen of Gal.
Interestingly, 6-sialyl-lactosamine, which like LSTc has a Neu-
NAc-a2,6-Gal-b1,4-GlcNAc motif, was not recognized by JCV
VP1. Since the oligosaccharide is directly linked to a lipid tag312 Cell Host & Microbe 8, 309–319, October 21, 2010 ª2010 Elsevie(Table S1), productive engagement of this compound might be
prevented because the GlcNAc group, which contributes
contacts in the case of LSTc, is in close proximity to the lipid
here. Thus, for reasons of accessibility, JCV requires at least
the LSTc pentasaccharide as a binding motif (Figure 3C).
The glycan array tested the effect of additional, branching resi-
dues to this minimal binding motif. Attachment of a fucose to
O3 of GlcNAc and O3 of Glc, or attachment of a branching oligo-
saccharide chain to O6 of Gal (probe 64, Figure 1A, Table S1),
would lead to clasheswith either JCV VP1 or other LSTc residues
(Figure 3D). Attachment of a fucose to O2 of the first Gal does not
occur in parallel with sialylation of that group. However, the pres-
ence of a GlcNAc residue instead of the terminal Glc of LSTc, as
present in most glycans carrying LSTc-like sequences, is
unlikely to alter the conformation of the oligosaccharide.
There are no hydrogen bonds between JCV VP1 and the
remaining three sugar moieties in LSTc. However, the Glc and
two Gal residues contribute to the surface area buried uponr Inc.
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structure, indicating low flexibility due to van der Waals interac-
tions with VP1. These interactions are clearly relevant for affinity
and specific binding of JCV, as demonstrated by the glycan mi-
croarray.
JCV VP1 Undergoes Induced-Fit Movements
upon Binding LSTc
To determine whether JCV VP1 undergoes conformational
changes upon ligand binding, we solved the structure of unli-
ganded JCV VP1 at 1.95 A˚ resolution (Table 1). Comparison
with liganded VP1 shows that residues in the binding site rear-
range upon ligand binding (Figure 3E). In the unliganded struc-
ture, the N264 side chain is oriented toward the side chains of
S266 and S268 and forms hydrogen bonds with both residues.
Upon ligand binding, N264 swings around to interact with
Q270 and theN-acetyl chain of NeuNAc. In the unliganded struc-
ture, the ‘‘binding’’ conformation of N264 is already present as
a second conformation, suggesting a dynamic equilibrium
between two conformations that is shifted by ligand binding.
More drastic changes are seen at residue N123, whose
hydrogen bonds are critical for recognizing the L-shaped binding
conformation of LSTc. In the absence of LSTc, the N123 side
chain points closer toward the NeuNAc binding site, and would
clash with NeuNAc. To accommodate NeuNAc, the N123 side
chain moves. Its altered position leads to clashes with main-
chain atoms in the BC2cw loop, and so residues 64–68 of the
BC2cw loop move to accommodate the new conformation of
N123. Induced-fit movements were not observed in receptor
interactions of SV40 and Polyoma (Neu et al., 2008; Stehle and
Harrison, 1997). The induced fit of JCV VP1may facilitate binding
to LSTc in a specific conformation.
Carbohydrate Binding Sites in VP1 Are Necessary
for JCV Attachment, Infection, and Spread
The crystal structure of VP1 in complex with LSTc revealed
numerous contacts between the protein and LSTc. To test
whether binding of LSTc is required for JCV infection, we intro-
duced point mutations in the oligosaccharide-binding sites of
VP1 into an infectious JCV clone (highlighted in Figure 4A).
One set of mutants was designed to abolish the interaction
with NeuNAc, either by removal of hydrogen bonds (S266A/
S268A) or by steric hindrance (S266N/S268N and L54Y). We
also probed the importance of N123, which undergoes
induced-fit movements to specifically recognize the L-shaped
conformation of LSTc, by mutating it to alanine. In addition, we
mutated A126 and R265 in a unique groove on the VP1 surface
(Figure 4A), which is not present in Polyoma and SV40 (Neu
et al., 2008; Stehle et al., 1994) and may be relevant for interac-
tionswith JCV cell surface receptors. In addition, R265 forms van
der Waals contacts with the long leg of LSTc. Mutants were
analyzed for infectious spread in long-term growth assays
(Figures 4B and 4D). On the final day of the growth assay, super-
natants were harvested and used to inoculate SVG-A cells for an
infectivity assay (Figures 4C and 4E). Mutation of residues in the
NeuNAc binding site (L54Y, S266A/S268A, and S266N/S268N)
completely abolished JCV spread and infectivity (Figures 4B
and 4C). Interactions mediated by each of these residues must
therefore be required for a productive interaction with sialicCell Hosacid, which in turn is essential for JCV growth. N123A had
delayed viral spread in culture compared to wild-type
(Figure 4D) and exhibited a 50% reduction in infectivity (Fig-
ure 4E), demonstrating the important role of N123 in accommo-
dating LSTc. Mutation of R265, which forms van der Waals
contacts with LSTc, did not affect growth and infectvity but
resulted in reduced binding (Figure 4F). Virus with a mutation in
the groove (A126Q) was capable of infection, and grew to levels
equivalent to wild-type JCV. This indicates that, while the groove
is unique to JCV VP1, residue A126 likely does not contribute to
receptor binding. Virus carrying themore drastic A126Ymutation
was unable to grow. We envisage that this mutation introduces
local structural changes that affect residues critical for sialic
acid binding.
The residues targeted for mutation are far from the VP1
regions that mediate capsid assembly or interact with minor
capsid proteins. In order to verify that the mutants do not alter
or destablize the structure of VP1, we introduced the mutations
into the pentamer expression construct and expressed mutant
proteins in E. coli. Like wild-type, all mutant proteins were puri-
fied as pentamers, indicating that they are properly folded
(Figure S1A). Circular dichroism spectroscopy experiments
confirm that secondary structure compositions of wild-type
and mutant proteins are identical (Figure S1B).
To determine whether the decrease in viral growth and infec-
tivity exhibited by mutant viruses was attributable to virus
binding, we analyzed wild-type and mutant JCV VP1 pentamers
in a flow cytometry-based cell-binding assay (Figure 4F). Purified
pentamers were incubated with SVG-A cells, and binding was
detected using an antibody specific for their His tag. Flow cytom-
etry analysis revealed that mutants that do not support infection
(L54Y, A126Y, S266A/S268A and S266N/S268N) or do so at
reduced levels (N123A) also have reduced binding to cells in
comparison to wild-type VP1. Mutants with wild-type-like
growth properties (A126Q, R265A) were capable of binding to
host cells. While A126Q bound similar to wild-type, R265A
exhibits reduced binding. As the R265 side chain forms van
der Waals contacts with LSTc (Figures 3 and 4), its mutation
likely results in a modest reduction of affinity that can be
compensated by avidity in the context of the virion and thus
does not affect viral growth and infectivity. These data demon-
strate that the specific contacts between JCV VP1 and LSTc
observed in the crystal structure play a critical role in JCV attach-
ment and infection.
Structural Basis for the Binding Specificity of JCV
The crystal structure provides a platform for understanding the
binding properties of JCV VP1 to host cells. Comparison with
the structure of SV40 VP1 in complex with its receptor GM1,
which carries an a2,3-linked NeuNAc at a branching point
(Figure 1B), reveals that JCV and SV40 bind terminal NeuNAc
at the same location in the VP1 pentamer (Neu et al., 2008).
The specific interactions with the functional groups of NeuNAc
are conserved (Figure 5), highlighting their importance.
However, the JCV and SV40 VP1 proteins differ at the cavity
into which the methyl group of the terminal NeuNAc inserts.
In SV40 VP1, this cavity is quite large, polar at its rim, and likely
water filled, while the cavity is smaller and more hydrophobic in
JCV. This reflects the different host organisms of the two viruses.t & Microbe 8, 309–319, October 21, 2010 ª2010 Elsevier Inc. 313
Figure 4. Growth, Infectivity, and Binding of JCV VP1 Mutants
(A) Point mutations introduced into JCV VP1. LSTc is shown in stick representation.
(B) Growth of JCV VP1 wild-type and mutant viruses. SVG-A cells were transfected with linearized DNA from JCV VP1 wild-type and mutant constructs. Trans-
fected cells were fixed and stained at day 4 posttransfection, then at 3 day intervals for 22 days by indirect immunofluorescence. Transfected or infected cells
were quantified based on nuclear VP1 staining. Each data point represents the average number of infected cells per visual field for ten fields of view for three
independent experiments. Error bars indicate SD.
(C) Infectivity of supernatants from JCV VP1 wild-type andmutant viruses. SVG-A cells were inoculated with supernatants harvested from infected cells at day 22
from (B). Cells were fixed and stained by indirect immunofluorescence at 72 hr postinfection and quantified based on nuclear VP1 staining. The results are pre-
sented as the average number of infected cells per visual field for ten visual fields from three individual samples performed in triplicate. Error bars indicate SD.
(D) Growth of JCV VP1wild-type andN123A. N123Awas analyzed for viral growth as in (B). Each data point represents the average of number of infected cells per
visual field for ten fields of view for three independent experiments. Error bars indicate SD. *p < 0.05.
(E) Infectivity of supernatants from JCV VP1 wild-type and N123A. N123A was analyzed for infectivity as in (C). Error bars indicate SD. *p < 0.05.
(F) Cell-binding analysis of JCV wild-type and mutant pentamers. SVG-A cells were incubated with His-tagged wild-type or mutant pentamers and a Penta His
Alexa Fluor 488 antibody. Cells were fixed and pentamer binding was analyzed by flow cytometry. Histograms represent the fluorescence intensity of Alexa 488
for antibody alone (filled) and pentamer samples (open) for 10,000 gated events. Data are grouped into two histograms based onmutants that propagate (bottom)
or do not propagate (top) in SVG-A cells.
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Figure 5. Comparison of Oligosaccharide
Binding Sites of JCV and SV40 VP1
(A) JCV VP1 in complex with LSTc. (B) SV40 VP1 in
complex with GM1. The Glc in GM1 does not
contact the protein and was omitted for clarity.
The proteins are shown in surface representation,
with the BC and HI loops also indicated in cartoon
representation. Residues contributing to ligand
binding or specificity are shown in stick represen-
tation. They are colored gray when they are in the
same conformation in the two proteins. Residues
that are not conserved and assume different
conformations are colored pink for JCV and blue
for SV40. A blue sphere indicates the Ca position
of G131 in SV40. The carbohydrate ligands are
shown as orange sticks. Key hydrogen bonds
are shown as black dashes.
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JCV Attachment to Its Glycan Receptor Motif LSTcIn simians, the natural hosts of SV40, the predominant sialic acid
is not NeuNAc but N-glycolyl neuraminic acid (NeuNGc), which
carries the larger and more polar CH2-OH group instead of the
methyl group of NeuNAc (Varki, 2001). SV40 binds to NeuNGc-
GM1 better than to NeuNAc-GM1 (Campanero-Rhodes et al.,
2007), which is consistent with its larger, more polar cavity.
However, NeuNAc is the most abundant sialic acid in humans,
and the smaller and more hydrophobic cavity of JCV is consis-
tent with its preference of NeuNAc-LSTc over NeuNGc-LSTc.
Thus, the structure of the oligosaccharide binding site has
consequences for the species specificity of the virus.
The position of NeuNAc in the larger context of an oligosac-
charide is clearly a major determinant of specificity (Figures 3C
and 3D). Amino acid N123 is key to recognizing the observed
L-shaped conformation of LSTc, since it makes hydrogen bonds
with both the GlcNAc and terminal NeuNAc sugar residues
(Figures 3A and 3B). Different linkages of NeuNAc, Gal, and
GlcNAc would not produce the precise arrangement of NeuNAc
and GlcNAc that is required for complex formation. As a result,
sialylparagloboside, which carries a2,3-linked NeuNAc but is
otherwise identical in sequence to LSTc, is not recognized
(Figure 1). The residue corresponding to N123 in SV40 is
a glycine, which would not be able to mediate these contacts
(Figure 5), explaining why SV40 does not attach to sequences
terminating in NeuNAc-a2,6-Gal-b1,4-GlcNAc (Campanero-
Rhodes et al., 2007; Neu et al., 2008).
Our data therefore provide strong support for a mode of
binding that requires both a terminal NeuNAc and the extended
L-shaped binding conformation of LSTc in the context of a long,
linear chain.
DISCUSSION
We demonstrate here by glycan array screening that recombi-
nant JCV VP1 pentamers selectively bind the LSTc oligosaccha-
ride. The observed interaction is of physiologic relevance, as
JCV infection can be blocked specifically by incubation with
soluble LSTc. In order to understand the molecular basis for
this recognition, we determined the structure of the JCV capsid
protein, VP1, in complex with LSTc at 2.0 A˚ resolution. The struc-
ture shows that JCV engages both the terminal sialic acid and
the unique L-shaped conformation of LSTc, which results in
additional contacts of the GlcNAc moiety with VP1 and likely isCell Hosa key determinant of its interaction with JCV VP1. Mutagenesis
of residues involved in sialic acid binding results in viruses that
are unable to grow and infect due to a binding defect.
Our finding that glycans terminating in the LSTc motif serve as
main receptors for JCV is consistent with biochemical assays
involving natively glycosylated cells (Liu et al., 1998b) (Figure 1B).
Homologs of LSTc, in which a GlcNAc replaces the terminal
Glc, are present in the human body as the termini of long oligo-
saccharide chains of the ‘‘i’’ antigen type (Feizi, 1985). All of the
glycans terminating in GlcNAc-LSTc contain repeating units of
[3-Gal-b1,4-GlcNAc-b1-]n (polyLacNAc repeats), and fulfill the
steric condition of a long carbohydrate that is unbranched at
its tip. These compounds should therefore bind JCV. The i
antigen is expressed on a high proportion of human peripheral
lymphocytes (Feizi et al., 1980). Glycan profiling by mass spec-
trometry has identified long glycans consistent with the LSTc
motif in theN-glycan fractions of several human tissues including
kidney, lung, and spleen (http://www.functionalglycomics.org/),
but tissues of the entire CNS were not analyzed. Lectin staining
of human tissues revealed that a2,6-linked NeuNAc is present on
the surface of B lymphocytes of the tonsils and spleen, on kidney
and lung cells, as well as on astrocytes and oligodendrocytes
(Eash et al., 2004). Only very low-level lectin staining was seen
for neurons and T lymphocytes. Notably, neurons, which
express the serotonin receptor, are not susceptible to infection
with JCV, most likely because they lack the oligosaccharide
receptor. As the expression pattern of LSTc-carrying glycans
corresponds to sites of JCV persistence (the kidney), and path-
ogenesis (the glial cells of the CNS), it is likely that the observed
specificity of JCV for LSTc contributes to targeting the virus to
these sites.
Previous studies report that JCV was also able to use a2,3-
linked sialic acids as receptors (Dugan et al., 2008). It is possible
that our glycan microarrays performed with pentamers failed
to detect low-affinity interactions of JCV with a2,3-linked
compounds because pentamers bind with much lower avidity
than virions. However, given the strong signal observed for
LSTc, such interactions would be very weak. Inspection of the
structure shows that linear a2,3-linked compounds would not
be able to interact favorably with JCV VP1. However, branched
compounds such as GM1 and GM2 would be able to bind, albeit
with significantly lower affinity compared to LSTc because of
their much smaller contact areas. Interestingly, unpublishedt & Microbe 8, 309–319, October 21, 2010 ª2010 Elsevier Inc. 315
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Glycomics (CFG), which are available online at http://www.
functionalglycomics.org/ according to CFGpolicy, confirm these
predictions. In glycan array screens of JCV VLPs of Mad-1
(which has the sameVP1 as the strain used in our studies), strong
binding was observed to LSTc-containing sequences, and weak
binding was observed for GM2, GM1, and similar short,
branched, a2,3-linked sequences. The weaker interactions
with GM1 and GM2 would not appear to be functional because
SV40, which does use GM1 as a receptor, does not compete
with JCV for binding sites (Liu et al., 1998a).
In contrast to the related polyomaviruses SV40, Polyoma, and
BKV, JCV does not enter cells by cholesterol-dependent endo-
cytosis but instead uses clathrin-mediated endocytosis. It is
enticing to speculate that this difference is reflected by their
carbohydrate receptor specificities. SV40, Polyoma, and BKV
all use gangliosides (Low et al., 2006; Tsai et al., 2003), which
in the case of SV40 initiate entry by inducing curvature of the
plasma membrane (Ewers et al., 2010). To induce curvature
upon binding, the oligosaccharide portion of the receptor must
be relatively rigid, which is the case for short, branched ganglio-
sides (Acquotti et al., 1991), but not for long, flexible polyLacNAc
extensions. Thus, the few amino acid changes between JCV and
related polyomaviruses might not only determine receptor spec-
ificity but also target the virus to a different entry pathway.
Statistical analyses of JCV sequences demonstrate that 52%
of PML patients carry JCV with one mutation in VP1 (L54F,
K59M/E/N, N264D/T, S266F/L, or S268F/Y/C) that likely arose
from positive selection (Sunyaev et al., 2009). Residues L54,
N264, S266, and S268 mediate direct contacts with NeuNAc.
Mutation of any of these four residues therefore adversely affects
sialic acid binding (Figures 3A and 4). Consistently, the L54F and
S268F mutants have reduced hemagglutination activity
(Sunyaev et al., 2009). Although residue K59 also contacts Neu-
NAc, its replacement with M, E, or N would still allow for similar
contacts. Not all of the mutations can therefore be attributed to
a selective pressure on the virus to alter its receptor binding site.
It is interesting to speculate about how mutations that should
block LSTc binding would be selected for in individuals with
PML. It is conceivable that JCV featuring amutated oligosaccha-
ride binding site can spread more rapidly to the CNS from its site
of persistence in the kidney because of diminished attachment
to carbohydrates. This scenario would be similar to a point muta-
tion in Polyoma VP1 that abolishes binding to nonfunctional
pseudoreceptors, thereby increasing viral spread and rendering
the virus more pathogenic (Freund et al., 1991). However,
a defect in sialic acid binding would abolish engagement of
both LSTc-carrying glycans and branched a2,3-linked
compounds. Unpublished glycan array screening data by
Leonid Gorelik and the CFG confirms this (http://www.
functionalglycomics.org/). One also cannot ascertain whether
JCV develops mutations in VP1 while replicating in remote sites
of infection such as the kidney or if they develop in the brain.
Moreover, it is not clear if patients carryingmutant JCV also carry
wild-type JCV. Finally, viruses with the mutations L54Y, S266A/
S268A, and S266N/S268N in the sialic acid binding site were
unable to infect cells and propagate in a long-term growth assay
because of a cell binding defect (Figure 4). Since wemutated the
residues identified in PML patients, albeit to different amino316 Cell Host & Microbe 8, 309–319, October 21, 2010 ª2010 Elsevieacids, we would predict that the mutations present in PML
patients would not propagate efficiently in glial cells.
In recent years, the incidence of PML has increased beyond
the HIV/AIDS population to include patients undergoing immu-
nosuppressive therapies for immunological disorders such as
multiple sclerosis (Linda et al., 2009; Wenning et al., 2009),
Crohn’s disease (Van Assche et al., 2005), rheumatoid arthritis,
and systemic lupus erythematosus (Carson et al., 2009a). Treat-
ment options for PML are currently inadequate (Kishida, 2007),
especially given the rapid devastation of this disease. We expect
that knowledge about the structure of JCV VP1 and its interac-
tion with receptors can serve as a platform from which such
treatment strategies can be developed.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
cDNA coding for amino acids 22–289 of the Mad-1 strain of JCV VP1 was
cloned into the pET15b expression vector (Novagen) in frame with an
N-terminal hexahistidine tag (His tag) and a thrombin cleavage site. The
N-terminal truncation was made because presence of these amino acids
had inhibited crystallization of the homologous Polyoma VP1, while the
C-terminal truncation was made to prevent capsid assembly in crystallization
setups (Stehle and Harrison, 1997). Mutations were introduced using Phusion
mutagenesis (NEB) according to the manufacturer’s instructions and
confirmed by sequencing (Table S2). Proteins were overexpressed in E. coli
BL21(DE3) and purified using nickel affinity chromatography. For glycan array
screening, flow cytometry, and circular dichroism, the proteins were addition-
ally purified by gel filtration. For crystallization, the His tag was removed by
incubation with thrombin prior to gel filtration. After cleavage, the nonnative
amino acid sequence GSHM remains at the N terminus of VP1.
Glycan Array Screening
The microarray was composed of 87 sequence-defined lipid-linked oligosac-
charide probes: 81 sialyl-terminating probes and six neutral probes as nega-
tive controls (Table S1). The probes were robotically printed in duplicate on
nitrocellulose-coated glass slides at 2 and 5 fmol per spot using a noncontact
instrument (Palma et al., 2006). The protein was precomplexed with mouse
monoclonal anti-poly-histidine (Ab1) and biotinylated anti-mouse IgG anti-
bodies (Ab2) (both from Sigma) in a ratio of 4:2:1 (by weight). In brief, the
JCV VP1-His tagged protein-antibody precomplexes were prepared by prein-
cubating Ab1 with Ab2 for 15min at ambient temperature, followed by addition
of VP1 and incubation for a further 15min on ice. The VP1-antibody complexes
were diluted in 5mMHEPES (pH 7.4), 150mMNaCl, 0.3% (v/v) Blocker Casein
(Pierce), 0.3% (w/v) bovine serum albumin (Sigma), 2.5 mM DTT, and 5 mM
CaCl2 to give a final VP1 concentration of 150 mg/ml, and overlaid onto the
arrays at 20C for 2 hr. Binding was detected with Alexa Fluor 647-labeled
streptavidin (Molecular Probes) and imaging (Palma et al., 2006), and data
analysis (Stoll and Feizi, 2009) was as described.
Crystallization and Data Collection
JCV VP1was concentrated to 4.5 mg/mL and crystallized by sitting drop vapor
diffusion at 20C. The reservoir solution contained 12% (w/v) PEG 3,350, 0.1M
HEPES (pH 7.5), and 0.2 M KSCN. Drops were set up by mixing 1 ml protein
solution with 1 ml reservoir solution and 0.2 ml microseeding stock from previ-
ously obtained crystals. Crystals were harvested into a solution containing
10% PEG 3,350, 0.1 M HEPES (pH 7.5), and 0.2 M KSCN and cryoprotected
by soaking for 10 s in harvesting solution containing 30% (v/v) glycerol and
flash freezing in liquid nitrogen. For complex formation, crystals were soaked
for 3 min in harvesting solution supplemented with 5 mM LSTc oligosaccha-
ride. The cryoprotecting solution also contained the same concentration of
LSTc oligosaccharide.
Structure Determination
Data reduction was performedwith XDS (Kabsch, 2010), and the structure was
solved bymolecular replacement in Phaser (McCoy et al., 2007) using a searchr Inc.
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was then performedwith Phenix and Refmac5 (Adams et al., 2010; Murshudov
et al., 1997), andmodel building was done in Coot (Emsley and Cowtan, 2004).
Five-fold noncrystallographic symmetry restraints were used throughout the
refinement for most of the protein. In data from crystals soaked in LSTc, the
ligand was located in 2Fo–Fc and Fo–Fc weighted electron density maps. The
ligand was refined using restraints from the CCP4 library, with the exception
of the a2,6-glycosidic bond, which had to be user defined. Waters were incor-
porated using Coot and ARP/wARP. The final models have good stereochem-
istry and agree very well with the experimental data (Table 1).
Cells, Viruses, and Antibodies
SVG-A cells are a subclone of the human glial cell line SVG transformedwith an
origin-defective SV40 mutant (Major et al., 1985). SVG-A cells were grown in
Minimum Essential Medium supplemented to contain 10% fetal bovine serum
(FBS) and penicillin/streptomycin (P/S) (Mediatech, Inc.) in a humidified incu-
bator at 37C. MAB597 is a hybridoma supernatant that produces a mono-
clonal antibody against JCV VP1 (Atwood et al., 1995) and was generously
provided by Ed Harlow. Penta His Alexa Fluor 488 was used at 10 mg/mL
(QIAGEN). Generation and propagation of the Mad-1/SVE strain of JCV were
performed as previously described (Vacante et al., 1989).
Viral Growth and Reinfection Assays
VP1 mutations were generated in the genomic JCV DNA of strain JC12 (Chen
and Atwood, 2002), subcloned in puc19 (Gee et al., 2004) with QuikChange
(Stratagene) according to the manufacturer’s instructions (Table S2), and
confirmed by sequencing. Of plasmid DNA, 10 mg was digested with BamHI
(Promega) for 2 hr at 37C to separate the JCV genomic DNA from the
puc19 backbone plasmid. Digests were performed in triplicate for each
sample. SVG-A cells were plated to 40% confluence on 18 mm round glass
coverslips (Thermo Scientific) in 12-well plates (Costar). Cells in medium
without antibiotics were transfected with 2 mg of digested DNA using Fugene
(Roche) at 3:2 ratio (Fugene:DNA). Transfected cells were incubated at 37C
O/N, and medium containing 5% FCS and 2% P/S was added to cells the
next day. Cells were incubated at 37C and fed with 500 ml of medium contain-
ing 5% FBS, 1% P/S, and 1% amphotericin B (Mediatech) or harvested for
immunofluorescence at day 4 and at 3 day intervals thereafter for 22 days.
For reinfection assays, supernatants were collected at 22 days posttransfec-
tion. SVG-A cells at 70%confluence on 22mm square glass coverslips (Fisher)
in 6-well plates (Costar) were infected with 150 ml of virus supernatant at 37C
for 1 hr, then medium containing 5% FBS, 1% P/S, 1% amphotericin B was
added to cells, and cells were incubated at 37C for 72 hr. Cells were fixed
and stained by indirect immunofluorescence.
Indirect Immunofluorescence
Cells were washed in PBS, fixed in cold MeOH, and incubated at20C. Cells
were washed in PBS, permeabilized with 0.5% TX-100 (USB Corporation) at
RT for 15 min, blocked with 10% goat serum (MP Biomedicals)/PBS at RT
for 30 min, incubated with VP1-specific antibody MAB597 (1:10) in PBS at
37C for 1 hr, washed with PBS, incubated with a goat-anti-mouse Alexa Fluor
488 (1:1000) in PBS at 37C for 1 hr, then washed with PBS. Cells were then
mounted on slides using VectaShield with Dapi (Vector Laboratories Inc.).
Cells were analyzed for nuclear VP1 staining under a 203 objective using an
Eclipse 800 or Eclipse TE2000-U microscope (Nikon) equipped with an
ORCA-ER digital camera (Hamamatsu).
LSTc Inhibition Assay
JCV (Mad-1/SVE) was pretreated with 5 mM of LSTb or LSTc (V Labs, Inc.)
(diluted in sterile diH2O) in media containing 2% FCS on ice for 1 hr. SVG-A
cells in 96-well plates were prechilled at 4C for 30 min. JCV-LST complexes
were added to cells and incubated at 4C for 1 hr. Cells were washed with PBS
twice; media containing 10% FCS, 1% P/S, and 1% amphotericin B was
added; and cells were incubated at 37C for 72 hr. Cells were fixed and stained
by indirect immunofluorescence as described above.
Flow Cytometry
Wild-type and mutant JCV VP1 pentamers (100 ml) in PBS were incubated with
SVG-A cells in suspension on ice for 2 hr with occasional agitation. Cells wereCell Hoswashed, pelleted by centrifugation, and suspended in 100 ml of Penta His Alexa
Fluor 488 antibody (QIAGEN) (10 mg/mL) in PBS on ice for 1 hr. Cells were
washed, pelleted, and fixed in 1% paraformaldehyde and analyzed for pen-
tamer binding using a BD FACSCaliber (Benton, Dickinson, and Company)
flow cytometer equipped with a 488 nm excitation line. Data were analyzed
using BD CellQuestPro (Benton, Dickinson, and Company) and FlowJo (Tree
Star, Inc) software.
Statistical Analysis
Means for triplicate sampleswere compared using an unpaired Student’s t test
(Microsoft Excel). P values <0.05 were considered statistically significant.
ACCESSION NUMBERS
Coordinates and structure factor amplitudes were deposited with the RCSB
data bank (http://www.rcsb.org/) under accession codes 3NXD and 3NXG.
Structure figures were prepared with PyMol (Schro¨dinger Inc.).
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